CLEC12A plays an important role in immunomodulatory function and prognostic significance of patients with acute myeloid leukemia

References

• Tarumoto Y, Lin S, Wang J, et al. Salt-inducible kinase inhibition suppresses acute myeloid leukemia progression in vivo. Blood. 2020;135(1):56–70.
   PubMed Web of Science ®Google Scholar
• Xie G, Ivica NA, Jia B, et al. CAR-T cells targeting a nucleophosmin neoepitope exhibit potent specific activity in mouse models of acute myeloid leukaemia. Nat Biomed Eng. 2021;5(5):399–413.
   PubMed Web of Science ®Google Scholar
• Yu J, Jiang PYZ, Sun H, et al. Advances in targeted therapy for acute myeloid leukemia. Biomark Res. 2020;8:17.
   PubMed Web of Science ®Google Scholar
• Jiang Z, Sun H, Yu J, et al. Targeting CD47 for cancer immunotherapy. J Hematol Oncol. 2021;14(1):180.
   PubMed Web of Science ®Google Scholar
• Tian Z, Liu M, Zhang Y, et al. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies. J Hematol Oncol. 2021;14(1):75.
   PubMed Web of Science ®Google Scholar
• Zhang X-H, Chen J, Han M-Z, et al. The consensus from the Chinese Society of Hematology on Indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update. J Hematol Oncol. 2021;14(1):145.
   PubMed Web of Science ®Google Scholar
• Nagler A, Labopin M, Houhou M, et al. Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. J Hematol Oncol. 2021;14(1):53.
   PubMed Web of Science ®Google Scholar
• Frigault MJ, Dietrich J, Martinez-Lage M, et al. Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood. 2019;134(11):860–866.
   PubMed Web of Science ®Google Scholar
• Zhang J, Hu X, Wang J, et al. Immune receptor repertoires in pediatric and adult acute myeloid leukemia. Genome Med. 2019;11(1):73.
   PubMed Web of Science ®Google Scholar
• Tong C, Zhang Y, Liu Y, et al. Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma. Blood. 2020;136(14):1632–1644.
   PubMed Web of Science ®Google Scholar
• Huang R, Li X, He Y, et al. Recent advances in CAR-T cell engineering. J Hematol Oncol. 2020;13(1):86.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li Y, Cao W, et al. Single-cell analysis of target antigens of CAR-T reveals a potential landscape of "on-target, off-tumor toxicity”. Front Immunol. 2021;12:799206.
   PubMed Web of Science ®Google Scholar
• Kim MY, Yu K-R, Kenderian SS, et al. Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia. Cell. 2018;173(6):1439–1453.e19.
   PubMed Web of Science ®Google Scholar
• Mardiros A, Dos Santos C, McDonald T, et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood. 2013;122(18):3138–3148.
   PubMed Web of Science ®Google Scholar
• Casucci M, Nicolis di Robilant B, Falcone L, et al. CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood. 2013;122(20):3461–3472.
   PubMed Web of Science ®Google Scholar
• He X, Feng Z, Ma J, et al. Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia. Blood. 2020;135(10):713–723.
   PubMed Web of Science ®Google Scholar
• Jetani H, Garcia-Cadenas I, Nerreter T, et al. CAR T-cells targeting FLT3 have potent activity against FLT3-ITD + AML and act synergistically with the FLT3-inhibitor crenolanib. Leukemia. 2018;32(5):1168–1179.
   PubMed Web of Science ®Google Scholar
• Baumeister SH, Murad J, Werner L, et al. Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML/MDS and multiple myeloma. Cancer Immunol Res. 2019;7(1):100–112.
   PubMed Web of Science ®Google Scholar
• Gomes-Silva D, Atilla E, Atilla PA, et al. CD7 CAR T cells for the therapy of acute myeloid leukemia. Mol Ther. 2019;27(1):272–280.
   PubMed Web of Science ®Google Scholar
• Gurney M, Stikvoort A, Nolan E, et al. CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide. Haematologica. 2020;107:437–445.
   Web of Science ®Google Scholar
• Shang Y, Zhou F. Current advances in immunotherapy for acute leukemia: an overview of antibody, chimeric antigen receptor, immune checkpoint, and natural killer. Front Oncol. 2019;9:917.
   PubMed Web of Science ®Google Scholar
• Wang J, Wang W, Chen H, et al. C-type lectin-like molecule-1 as a biomarker for diagnosis and prognosis in acute myeloid leukemia: a preliminary study. Biomed Res Int. 2021;2021:6643948.
   PubMed Web of Science ®Google Scholar
• Sancho D, Sousa C. Signaling by myeloid C-type lectin receptors in immunity and homeostasis. Annu Rev Immunol. 2012;30:491–529.
   PubMed Web of Science ®Google Scholar
• Pare G, Vitry J, Merchant ML, et al. The inhibitory receptor CLEC12A regulates PI3K-Akt signaling to inhibit neutrophil activation and cytokine release. Front Immunol. 2021;12:650808.
   PubMed Web of Science ®Google Scholar
• Gagne V, Marois L, Levesque J-M, et al. Modulation of monosodium urate crystal-induced responses in neutrophils by the myeloid inhibitory C-type lectin-like receptor: potential therapeutic implications. Arthritis Res Ther. 2013;15(4):R73.
   PubMed Web of Science ®Google Scholar
• Sagar D, Singh NP, Ginwala R, et al. Antibody blockade of CLEC12A delays EAE onset and attenuates disease severity by impairing myeloid cell CNS infiltration and restoring positive immunity. Sci Rep. 2017;7(1):2707.
   PubMedGoogle Scholar
• Morsink LM, Walter RB, Ossenkoppele GJ. Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia. Blood Rev. 2019;34:26–33.
   PubMed Web of Science ®Google Scholar
• Larsen HØ, Roug AS, Just T, et al. Expression of the hMICL in acute myeloid leukemia—a highly reliable disease marker at diagnosis and during follow-up. Cytometry B Clin Cytom. 2012;82(1):3–8.
   PubMedGoogle Scholar
• Bakker ABH, van den Oudenrijn S, Bakker AQ, et al. C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia. Cancer Res. 2004;64(22):8443–8450.
   PubMed Web of Science ®Google Scholar
• Haubner S, Perna F, Köhnke T, et al. Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. Leukemia. 2019;33(1):64–74.
   PubMed Web of Science ®Google Scholar
• Zhao X, Singh S, Pardoux C, et al. Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia. Haematologica. 2010;95(1):71–78.
   PubMed Web of Science ®Google Scholar
• Wang J, Chen S, Xiao W, et al. CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia. J Hematol Oncol. 2018;11(1):7.
   PubMedGoogle Scholar
• Ma H, Padmanabhan IS, Parmar S, et al. Targeting CLL-1 for acute myeloid leukemia therapy. J Hematol Oncol. 2019;12(1):41.
   Google Scholar
• Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-Infiltrating immune cells. Cancer Res. 2017;77(21):e108–e110.
   PubMed Web of Science ®Google Scholar
• Barretina J, Caponigro G, Stransky N, et al. Addendum: the Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2019;565(7738):E5–E6.
   PubMed Web of Science ®Google Scholar
• Tang Z, Kang B, Li C, et al. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47(W1):W556–W560.
   PubMed Web of Science ®Google Scholar
• Barrett T, Wilhite SE, Ledoux P, et al. NCBI GEO: archive for functional genomics data sets-update. Nucleic Acids Res. 2013;41(Database issue):D991–D995.
   PubMed Web of Science ®Google Scholar
• Tomczak K, Czerwińska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol. 2015;19(1A):A68–A77.
   Google Scholar
• Li T, Fu J, Zeng Z, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509–W514.
   PubMed Web of Science ®Google Scholar
• Jiang P, Gu S, Pan D, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550–1558.
   PubMed Web of Science ®Google Scholar
• Wang Y-Y, Chen W-L, Weng X-Q, et al. Low CLL-1 expression is a novel adverse predictor in 123 patients with de novo CD34+ acute myeloid leukemia. Stem Cells Dev. 2017;26(20):1460–1467.
   PubMed Web of Science ®Google Scholar
• Wang H, Kaur G, Sankin AI, et al. Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies. J Hematol Oncol. 2019;12(1):59.
   PubMed Web of Science ®Google Scholar
• Qin VM, Haynes NM, D'Souza C, et al. CAR-T plus radiotherapy: a promising combination for immunosuppressive tumors. Front Immunol. 2021;12:813832.
   PubMed Web of Science ®Google Scholar
• Moore JW, Pelcovits A, Reagan JL. Azacitidine and venetoclax in AML. N Engl J Med. 2020;383(21):2088.
   PubMedGoogle Scholar
• Advani AS, Cooper B, Visconte V, et al. A phase I/II trial of MEC (mitoxantrone, etoposide, cytarabine) in combination with ixazomib for relapsed refractory acute myeloid leukemia. Clin Cancer Res. 2019;25(14):4231–4237.
   PubMed Web of Science ®Google Scholar
• DeWolf S, Tallman MS. How I treat relapsed or refractory AML. Blood. 2020;136(9):1023–1032.
   PubMed Web of Science ®Google Scholar
• De Moerloose B. CAR-T treatment of pediatric AML: a long and winding road. Blood. 2021;137(8):1004–1006.
   PubMed Web of Science ®Google Scholar
• Wermke M, Kraus S, Ehninger A, et al. Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML. Blood. 2021;137(22):3145–3148.
   PubMed Web of Science ®Google Scholar
• Willier S, Rothämel P, Hastreiter M, et al. CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy. Blood. 2021;137(8):1037–1049.
   PubMed Web of Science ®Google Scholar
• Rennert PD, Dufort FJ, Su L, et al. Anti-CD19 CAR T cells that secrete a biparatopic anti-CLEC12A bridging protein have potent activity against highly aggressive acute myeloid leukemia in vitro and in vivo. Mol Cancer Ther. 2021;20(10):2071–2081.
   PubMed Web of Science ®Google Scholar
• George B, Kantarjian H, Baran N, et al. TP53 in acute myeloid leukemia: molecular aspects and patterns of mutation. Int J Mol Sci. 2021;22(19):10782.
   PubMed Web of Science ®Google Scholar
• Hunter AM, Sallman DA. Current status and new treatment approaches in TP53 mutated AML. Best Pract Res Clin Haematol. 2019;32(2):134–144.
   PubMed Web of Science ®Google Scholar
• Li L, Liu X, Sanders KL, et al. TLR8-mediated metabolic control of human Treg function: a mechanistic target for cancer immunotherapy. Cell Metab. 2019;29(1):103–123.e5.
   PubMed Web of Science ®Google Scholar